

RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2026

Milan, 1st April 2026 – Please be informed that the **2025 Annual Financial Report** (including the Separate Financial Statements and the Consolidated Financial Statements as at 31st December 2025, together with the related Directors' Report on Operations, including the Consolidated Sustainability Statement, and the required Certifications), coupled with the **Reports issued by the Auditing Firm**, as well as the **Report issued by the Board of Statutory Auditors**, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.com - Investors – Shareholder Information section) and on the '1INFO' storage mechanism (www.1info.it).

In addition, please be informed that the following reports approved by the Board of Directors of Recordati S.p.A. on 19th March 2026, namely:

- (i) the **2025 Corporate Governance Report and Ownership Structure**; and
- (ii) the **Directors' Report relating to item no. 1** (Financial statements approval and allocation of profit) of the agenda of the Ordinary and Extraordinary Shareholders' Meeting called for 29th April 2026, in ordinary session,

are also available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.com), the first report in the Governance – Corporate Governance Report section; and the second report in the Investors - Shareholder Information section) and on the '1INFO' storage mechanism (www.1info.it).

***Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.*

Investor Relations

Eugenia Litz
Eugenia.Litz@recordati.com

Gianluca Saletta
saletta.g@recordati.it

Media Relations

Laura Conti
conti.l@recordati.it

Rebecca Kerr
rebecca.kerr@recordati.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office
VIA M. CIVITALI, 1
20148 MILAN, ITALY
TEL. +39 0248787.1
FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up
BUSINESS REGISTER OF MILAN, MONZA, BRIANZA and LODI 00748210150
TAX CODE/VAT NO. 00748210150
MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832

Company subject to management and coordination by Rossini Luxembourg S.à.r.l